Cell line · CVCL_0620
MDA-MB-361
Cancer cell line, Homo sapiens. Breast adenocarcinoma. 69 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MDA-MB-361. Cell lines, record CVCL_0620. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0620
On this page
Cell line
As Cellosaurus gives it.
- Name
- MDA-MB-361
- Accession
- CVCL_0620
- RRID
- RRID:CVCL_0620
- Synonyms
- MDA-MB 361, MDA MB 361, MDA-MB361, MDAMB361, MDA-361, MDA361, MB361, MD Anderson-Metastatic Breast-361
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 40Y
- Category
- Cancer cell line
- Diseases
- Breast adenocarcinoma (NCIt C5214)
- Derived from
- Brain (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers69
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PatientProfiler: building patient-specific signaling models from proteogenomic data. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 69
See all 69 papersRelatives2
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | DY36T2 | CVCL_EQ21 | Cell lines | |
| Derived from it | MDA-MB-361-Luc#1 | CVCL_4Y09 | Cell lines |
Cell banks5
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-27 | ATCC | |
| BCRC | 60549 | BCRC | |
| CLS | 305267 | CLS | |
| ECACC | 92020423 | ECACC | |
| NCBI_Iran | C433 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0620
GET https://conductscience.org/api/cell-lines/v1/CVCL_0620/papers?page=2